This includes the quantification of biomarkers including estrogen receptor (ER), progesterone receptor (PR), HER2 and Ki-67 (some of these are also prognostic factors) for targeted therapy, the response to NAC and risk categorization for adjuvant chemotherapy in ER-positive/HER2-negative breast cancer. Here, ERBB2 is linked to breast carcinoma.